JPWO2020004607A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020004607A5 JPWO2020004607A5 JP2020527674A JP2020527674A JPWO2020004607A5 JP WO2020004607 A5 JPWO2020004607 A5 JP WO2020004607A5 JP 2020527674 A JP2020527674 A JP 2020527674A JP 2020527674 A JP2020527674 A JP 2020527674A JP WO2020004607 A5 JPWO2020004607 A5 JP WO2020004607A5
- Authority
- JP
- Japan
- Prior art keywords
- aptamer
- aqueous liquid
- preparation according
- liquid preparation
- nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 claims 13
- 108091023037 Aptamer Proteins 0.000 claims 12
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 238000002360 preparation method Methods 0.000 claims 7
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000020084 Bone disease Diseases 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 208000015100 cartilage disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003792 electrolyte Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 230000003204 osmotic effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000002213 purine nucleotide Substances 0.000 claims 2
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 claims 2
- 239000002719 pyrimidine nucleotide Substances 0.000 claims 2
- 150000003230 pyrimidines Chemical class 0.000 claims 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 229940113082 thymine Drugs 0.000 claims 1
- 229940035893 uracil Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018124390 | 2018-06-29 | ||
| JP2018124390 | 2018-06-29 | ||
| PCT/JP2019/025766 WO2020004607A1 (ja) | 2018-06-29 | 2019-06-28 | アプタマー製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020004607A1 JPWO2020004607A1 (ja) | 2021-07-15 |
| JPWO2020004607A5 true JPWO2020004607A5 (enExample) | 2022-03-31 |
| JP7340264B2 JP7340264B2 (ja) | 2023-09-07 |
Family
ID=68986754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020527674A Active JP7340264B2 (ja) | 2018-06-29 | 2019-06-28 | アプタマー製剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210269802A1 (enExample) |
| EP (1) | EP3815715B1 (enExample) |
| JP (1) | JP7340264B2 (enExample) |
| KR (1) | KR102841342B1 (enExample) |
| CN (1) | CN112384246B (enExample) |
| AU (1) | AU2019292134B2 (enExample) |
| BR (1) | BR112020026634A2 (enExample) |
| CA (1) | CA3105002A1 (enExample) |
| ES (1) | ES2992308T3 (enExample) |
| IL (1) | IL279595B1 (enExample) |
| MX (1) | MX2020014124A (enExample) |
| SG (1) | SG11202012933QA (enExample) |
| TW (1) | TWI845521B (enExample) |
| WO (1) | WO2020004607A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021157681A1 (ja) | 2020-02-06 | 2021-08-12 | 株式会社リボミック | 網膜下高反射病巣または網膜下高反射病巣を伴う網膜疾患の治療剤 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
| US5847086A (en) * | 1991-06-20 | 1998-12-08 | Centeon L.L.C. | Therapeutic fragments of von Willebrand factor |
| MY147374A (en) * | 2006-11-14 | 2012-11-30 | Ribomic Inc | Aptamer against midkine and use thereof |
| CN101317820B (zh) * | 2007-04-19 | 2012-02-29 | 中国人民解放军军事医学科学院毒物药物研究所 | 生物亲和性配体分子介导的靶向脂质体，其制 备及其应用 |
| US20090203766A1 (en) * | 2007-06-01 | 2009-08-13 | Archemix Corp. | vWF aptamer formulations and methods for use |
| WO2009118108A1 (en) * | 2008-03-26 | 2009-10-01 | Merck Patent Gmbh | Method of long term storage of substrate-coupled beads |
| US9052323B2 (en) * | 2009-08-27 | 2015-06-09 | The University Of Kansas | Osmolyte mixture for protein stabilization |
| JP5899550B2 (ja) | 2010-02-12 | 2016-04-06 | 株式会社リボミック | Ｆｇｆ２に対するアプタマー及びその使用 |
| WO2014116789A1 (en) * | 2013-01-25 | 2014-07-31 | Thymon, Llc | Immunogenic and prophylactic compositions, methods of making same, and method for treating and preventing tnf-mediated disease and hiv-1 infection |
| KR102394676B1 (ko) * | 2014-03-24 | 2022-05-09 | 가부시키가이샤 리보믹 | Fgf2에 대한 압타머 및 그의 사용 |
| WO2015200539A1 (en) * | 2014-06-25 | 2015-12-30 | Monsanto Technology Llc | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
| JP2018124390A (ja) | 2017-01-31 | 2018-08-09 | 株式会社沖データ | 画像形成装置及び定着制御方法 |
-
2019
- 2019-06-28 BR BR112020026634-5A patent/BR112020026634A2/pt not_active Application Discontinuation
- 2019-06-28 AU AU2019292134A patent/AU2019292134B2/en active Active
- 2019-06-28 CA CA3105002A patent/CA3105002A1/en active Pending
- 2019-06-28 CN CN201980043745.7A patent/CN112384246B/zh active Active
- 2019-06-28 ES ES19825285T patent/ES2992308T3/es active Active
- 2019-06-28 WO PCT/JP2019/025766 patent/WO2020004607A1/ja not_active Ceased
- 2019-06-28 US US17/256,368 patent/US20210269802A1/en active Pending
- 2019-06-28 JP JP2020527674A patent/JP7340264B2/ja active Active
- 2019-06-28 TW TW108122887A patent/TWI845521B/zh active
- 2019-06-28 KR KR1020217002648A patent/KR102841342B1/ko active Active
- 2019-06-28 EP EP19825285.0A patent/EP3815715B1/en active Active
- 2019-06-28 SG SG11202012933QA patent/SG11202012933QA/en unknown
- 2019-06-28 MX MX2020014124A patent/MX2020014124A/es unknown
-
2020
- 2020-12-20 IL IL279595A patent/IL279595B1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2808049T3 (es) | Acido nucleico antisentido | |
| RU2730681C2 (ru) | Антисмысловые нуклеиновые кислоты | |
| CN107693797B (zh) | 肽寡核苷酸缀合物 | |
| CN106573920B (zh) | 用于在流感病毒感染中使用的吲哚 | |
| JP2015504650A5 (enExample) | ||
| ES2598555T3 (es) | Nuevos oligonucleótidos modificados ricos en guanosina y actividad antiproliferativa de los mismos | |
| JP2010536787A5 (enExample) | ||
| JP2016502858A5 (enExample) | ||
| AU2017326372B2 (en) | Modified oligonucleotides and methods of use | |
| TW201134482A (en) | Aptamers to β -NGF and their use in treating β -NGF mediated diseases and disorders | |
| JP2010536787A (ja) | Ｔｏｌｌ様受容体モジュレータ | |
| JP7022069B2 (ja) | ラパドシン（Ｒａｐａｄｏｃｉｎｓ）、受動拡散型ヌクレオシド輸送体１阻害剤及びその使用 | |
| JP2009521934A5 (enExample) | ||
| PE20210630A1 (es) | Composicion que comprende el oligonucleotido antisentido y su uso para el tratamiento de la distrofia muscular de duchenne | |
| US20170009230A1 (en) | Compositions for inhibiting dux4 gene expression and uses thereof | |
| JPWO2020004607A5 (enExample) | ||
| CN114574496A (zh) | 核苷类衍生物改性的核酸适体sgc8 | |
| US20200123546A1 (en) | Antisense nucleic acid for treating amyotrophy | |
| CN118109469A (zh) | 诱导外显子50的跳读的反义核酸 | |
| RU2016141263A (ru) | Аптамер для fgf2 и его применение | |
| RU2021101849A (ru) | Препарат аптамера | |
| WO2018183127A1 (en) | Mir-92 inhibitors for treatment of heart failure | |
| Kandimalla et al. | Single strand targeted triplex formation: targeting purine-pyrimidine mixed sequences using abasic linkers | |
| BR112020026634A2 (pt) | Preparação de aptâmero | |
| JPWO2021157681A5 (enExample) |